Item 8.01 Other Events
On November 30, 2021, Hepion Pharmaceuticals, Inc. (the "Company") issued a
press release announcing that the U.S. Food and Drug Administration has granted
Fast Track designation for the Company's lead drug candidate, CRV431, for the
treatment of NASH. A copy of the press release is furnished as Exhibit 99.1 to
this Form 8-K.
Item 9.01 Financial Statements and Exhibits
99.1 Hepion Pharmaceuticals, Inc. Press Release dated November 30,
104 Cover Page Interactive Data File. The cover page XBRL tags are
embedded within the inline XBRL document.
© Edgar Online, source Glimpses